JPMorgan lowered the firm’s price target on Novo Nordisk (NVO) to DKK 1,000 from DKK 1,050 and keeps an Overweight rating on the ...
Trademark prosecution data reveals how the rival healthcare companies are ensuring exclusivity internationally for their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback